Sanofi, Evotec, Apeiron in Accord for Cancer Immunotherapies
August 10 2015 - 2:03AM
Dow Jones News
PARIS--French drugmaker Sanofi (SAN.FR) said Monday it has
entered into an agreement to develop cancer immunotherapies with
German biotech company Evotec AG (EVT.XE) and Austria's Apeiron
Biologics.
The deal covers research collaboration and a license agreement
to discover and develop molecule-based immuno-oncology therapies
that treat cancers by boosting the anti-tumor activity of the human
immune system, Sanofi said.
Sanofi will have sole responsibility for all development,
regulatory, commercial and manufacturing activities of the
products. The French pharmaceutical group will provide two years of
funding for Evotec and Apeiron. If the project continues, Evotec
will be entitled to receive further milestone payments that could
total more than EUR200 million, as well as royalties on net sales,
Sanofi said.
-Write to William Horobin at william.horobin@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024